Comment
Abstract title
SINGLE INSTITUTION EXPERIENCE WITH NIVOLUMAB AS SECOND LINE THERAPY IN ADVANCED RENAL CELL CARCINOMA: EXPLORATORY ANALYSIS OF PROGNOSTIC FACTORS
First author
JURE MURGIĆ
Your name
Your E-mail address
Your message
